A cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kah Woon Teoh und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia. Hauptthemen laut MEDLINE: Prediabetic State, Community Pharmacy Services. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Monash University Malaysia Network for Equity through Digital Health (NEED), NEED.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Aims
This study assessed the cost‐effectiveness of a digital health‐supported and community pharmacy‐based lifestyle intervention (PRIME) programme for individuals with prediabetes in Malaysia over a 6‐month period. Materials and Methods A trial‐based cost‐effectiveness study with a 6‐month time horizon was conducted. Ninety‐one participants (intervention, n = 46; usual care, n = 45) across 13 community pharmacies were included. The intervention group received in‐depth counselling from pharmacists, in‐app prediabetes education modules and peer support, while the usual care group received counselling based on pharmacists' usual practice. The primary outcome was quality‐adjusted life years (QALY). Incremental cost‐effectiveness ratios (ICER) per QALY gained of the intervention were compared with usual care from healthcare and societal perspectives. Non‐parametric bootstrapping was used to examine uncertainty.
Results
At 6months, the QALY achieved was 0.467 (95% CI 0.456 to 0.479) in the intervention group and 0.466 (95% CI 0.451 to 0.482) in the usual care group, resulting in a net gain of 0.005 QALY (95% CI −0.017 to 0.026) in the intervention group. The incremental healthcare and societal costs were US$6.10 (95% CI $5.33 to $6.88) and $10.69 (95% CI $6.03 to $15.35), respectively. From a healthcare perspective, the ICER per QALY gained was $1354, with a probability of 69.2% being cost‐effective, while the corresponding figures were $2371 and 67.7% from a societal perspective. Results were below the willingness‐to‐pay threshold at $11 845 and were robust to sensitivity analyses.
Conclusion
A community pharmacy‐based and digital health‐supported lifestyle intervention to manage prediabetes may be cost‐effective compared with usual care in Malaysia over a 6‐month period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
- Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Kah Woon Teoh, Shaun Wen Huey Lee
Förderung
- The Monash University Malaysia Network for Equity through Digital Health (NEED)
- NEED
Zitieren
APA
Teoh, K. W., Baek, Y., Ademi, Z., & Lee, S. W. H. (2025). A cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16350
Vancouver
Teoh KW, Baek Y, Ademi Z, Lee SWH. A cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16350
BibTeX
@article{Teoh2025,
author = {Teoh, Kah Woon and Baek, Yeji and Ademi, Zanfina and Lee, Shaun Wen Huey},
title = {A cost‐effectiveness analysis alongside trial of a digital health‐supported and community pharmacy‐based prediabetes management programme ( PRIME Programme) in Malaysia},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16350}
}
EUVIMED